Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma

Ahn, Seo-Yeon; Kwon, Seong; Jung, Sung-Hoon; Ahn, Jae‐Sook; Yoo, Su Woong; Min, Jung‐Joon; Bom, Hee‐Seung; Ki, So Yeon; Kim, Hyeoung-Joon; Lee, Je‐Jung; Song, Sang Yun; Yang, Deok‐Hwan

doi:10.1097/rlu.0000000000002154

Cited by 21 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, all the authors claim that this study may complement the pre-operative localization diagnostics of patients with primary hyperparathyroidism, in whom standard double-tracer subtraction scintigraphy and ultrasound do not provide a clear result allowing for effective MIP surgery [40,41]. In addition, some authors show evidence of the superiority of PET/CT diagnostics with 11C-MET over scintigraphy in patients who have previously undergone surgical treatment and who have recurrent hyperparathyroidism [42,43]. Due to the larger scope of the PET/CT scan compared to the scintigraphy, it may also have an advantage in patients with ectopic lesions and multiple lesions, which are more common in secondary and tertiary hyperparathyroidism (e.g.…”

Section: The Use Of Pet/ct With 11c-methionine In the Diagnosis Of Hymentioning

confidence: 90%

The Role of Pet/Ct With 11c-Methionine in Contemporary Nuclear Medicine

et al. 2020

View full text Add to dashboard Cite

Positron emission tomography (PET/CT) is a non-invasive molecular imaging technique using isotopes with a short half-life usually in combination with chemical compounds. The most commonly used PET/CT tracer is 2-fluoro-2-deoxy-D-glucose labeled with fluorine (18-FDG). It is used mainly in oncological diagnostics as well as myocardial viability, epilepsy and inflammatory diagnostics. The tracer less commonly used in PET/CT could be carbon-labeled methionine (11C-MET). It is mainly used in the diagnosis of focal lesions in the central nervous system. There are also reports of the use of this tracer in diagnostics of the primary, secondary and tertiary hyperparathyroidism as well as multiple myeloma. This tracer may also be used in the diagnosis of lymphoproliferative diseases and solid tumors, although there is no clear evidence of its advantage over 18-FDG. Conclusion: Significant difficulties in the production and transport of this tracer and lack of reimbursement of this type of procedure in Poland limits the use of this tracer for scientific research.

show abstract

Section: The Use Of Pet/ct With 11c-methionine In the Diagnosis Of Hymentioning

confidence: 90%

The Role of Pet/Ct With 11c-Methionine in Contemporary Nuclear Medicine

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Few studies have investigated the role of MET PET for response assessment ( 139 , 141 , 142 ). One prospective study in 26 patients ( 139 ) assessed the value of interim MET PET/CT and MRI after four cycles of high doseMTX-based induction chemotherapy and noted an interim response discrepancy between MET PET and brain MRI in four patients, with a negative PET but MR showing contrast-enhancing lesions. All four patients achieved complete remission following treatment; thus, PET may enable detection of response at an earlier timepoint.…”

Section: Pet Imagingmentioning

confidence: 99%

“…All four patients achieved complete remission following treatment; thus, PET may enable detection of response at an earlier timepoint. One study also suggested that MET PET/CT may enable prediction of patient outcome ( 139 ).…”

Section: Pet Imagingmentioning

confidence: 99%

Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review

et al. 2021

View full text Add to dashboard Cite

This review addresses the challenges of primary central nervous system (CNS) lymphoma diagnosis, assessment of treatment response, and detection of recurrence. Primary CNS lymphoma is a rare form of extra-nodal non-Hodgkin lymphoma that can involve brain, spinal cord, leptomeninges, and eyes. Primary CNS lymphoma lesions are most commonly confined to the white matter or deep cerebral structures such as basal ganglia and deep periventricular regions. Contrast-enhanced magnetic resonance imaging (MRI) is the standard diagnostic modality employed by neuro-oncologists. MRI often shows common morphological features such as a single or multiple uniformly well-enhancing lesions without necrosis but with moderate surrounding edema. Other brain tumors or inflammatory processes can show similar radiological patterns, making differential diagnosis difficult. [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) has selected utility in cerebral lymphoma, especially in diagnosis. Primary CNS lymphoma can sometimes present with atypical findings on MRI and FDG PET, such as disseminated disease, non-enhancing or ring-like enhancing lesions. The complementary strengths of PET and MRI have led to the development of combined PET-MR systems, which in some cases may improve lesion characterization and detection. By highlighting active developments in this field, including advanced MRI sequences, novel radiotracers, and potential imaging biomarkers, we aim to spur interest in sophisticated imaging approaches.

show abstract

“…They also demonstrated the potential of CXCR4 as a theranostic target in MM patients in a pilot study confirming the feasibility of CXCR4-directed radionuclide therapy using 177 Lu or 90 Y-CXCR4 ligand (pentixather) as a novel treatment approach for MM [ 39 ]. Interestingly, compared to 18 FDG, 68 Ga-pentixafor also seems to be a promising imaging tool for assessment of other related blood cancers including MALT lymphoma [ 40 ], Waldenström macroglobulinemia, lymphoplasmacytic lymphoma [ 41 ] and primary central nervous system lymphoma [ 42 ]. Furthemore, the use of 11C-methionine (MET) in MM also seems to have a promising future.…”

Section: Perspectivementioning

confidence: 99%

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?

Michaud-Robert

Jamet

Bailly

et al. 2020

Cancers

View full text Add to dashboard Cite

Multiple myeloma (MM) is a haematological neoplasm characterized by a clonal proliferation of malignant plasma cells in the bone marrow. MM is associated with high morbidity and mortality and variable survival, which can be very short for some patients but over 10 years for others. These differences in survival are explained by intra- and inter-tumoral heterogeneity and demonstrate the potential benefits of adapting the treatment course for high-risk patients with a poorer prognosis. Indeed, identification of these high-risk patients is necessary and is based on the identification of high-risk biomarkers including clinical variables, genomics and imaging results. Positron emission tomography combined with computed tomography using 18F-deoxyfluoroglucose (FDG-PET/CT) is a reliable technique for the initial staging of patients with symptomatic multiple myeloma (MM), and has been included in the IMWG (International Myeloma Working Group) recommendations in 2019. According to clinical studies, FDG-PET/CT characteristics could be used to define high-risk patients at initial diagnosis of symptomatic MM. The goal of this review is to demonstrate the prognostic value of FDG-PET in symptomatic MM patients, particularly in identifying high-risk patients, and thus, to best adapt therapeutic management in the future.

show abstract

Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma

Abstract: Response assessments based on interim C-MET PET/CT could predict the therapeutic outcome of PCNSL.

Cited by 21 publications

References 28 publications

The Role of Pet/Ct With 11c-Methionine in Contemporary Nuclear Medicine

The Role of Pet/Ct With 11c-Methionine in Contemporary Nuclear Medicine

Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?

Contact Info

Product

Resources

About